TOP > 外国特許検索 > PREVENTIVE AGENT OR THERAPEUTIC AGENT FOR RENAL DISORDERS

PREVENTIVE AGENT OR THERAPEUTIC AGENT FOR RENAL DISORDERS

外国特許コード F210010301
整理番号 (FU876)
掲載日 2021年1月29日
出願国 世界知的所有権機関(WIPO)
国際出願番号 2020JP001598
国際公開番号 WO 2020255464
国際出願日 令和2年1月17日(2020.1.17)
国際公開日 令和2年12月24日(2020.12.24)
優先権データ
  • 特願2019-114970 (2019.6.20) JP
発明の名称 (英語) PREVENTIVE AGENT OR THERAPEUTIC AGENT FOR RENAL DISORDERS
発明の概要(英語) Provided is a novel preventive agent or therapeutic agent for renal disorders. This preventive agent or therapeutic agent for renal disorders contains a thioredoxin derivative as an active ingredient.
従来技術、競合技術の概要(英語) BACKGROUND ART
Renal disorders are diseases with high mortality and poor prognosis. For example, in severe acute nephropathy (acute kidney injury: AKI), the mortality rate is greater than 50 %.
Upon transition (AKI to CKD transition) from acute renal injury to chronic renal disease, some of the patients need to undergo dialysis. The number of patients who required dialysis due to the transition from acute renal injury to chronic renal disease has been said to reach approximately 80,000 dialyzed patients in Japan at approximately 1/4 (approximately 80,000 people).
Research has been underway on the mechanism of transitioning from acute renal injury to chronic renal disease. (Non-Patent Document 1) has been reported that stopping of the cell cycle of renal cells without progression from phase G2 to phase m is one of the mechanisms of transitioning from acute renal injury to chronic renal disease.
Furthermore, renal disorders can be classified into various classes, and examples of renal disorders include a transition from acute renal disorder to chronic renal disease, calcineurin inhibitor nephropathy, diabetic kidney disease, renal sclerosis, and renal disorders due to ischemia, oxidative stress, or renal interstitial fibrosis, such as renal disorders associated with renal transplantation.
Under the circumstances described above, attention has attracted attention to the development of prophylactic agents and therapeutic agents for renal disorders. For acute renal disorders associated with cardiac surgery, methods of treating patients with the inhibitor (QPI-1002) of p53 are currently in progress and for which a Phase III trial is currently being conducted.
  • 出願人(英語)
  • ※2012年7月以前掲載分については米国以外のすべての指定国
  • UNIVERSITY OF FUKUI
  • NONPROFIT ORGANIZATION JAPAN BIOSTRESS RESEARCH PROMOTION ALLIANCE
  • 発明者(英語)
  • KASUNO, Kenji
  • IWANO, Masayuki
  • YODOI,Junji
国際特許分類(IPC)
指定国 National States: AE AG AL AM AO AT AU AZ BA BB BG BH BN BR BW BY BZ CA CH CL CN CO CR CU CZ DE DJ DK DM DO DZ EC EE EG ES FI GB GD GE GH GM GT HN HR HU ID IL IN IR IS JO JP KE KG KH KN KP KR KW KZ LA LC LK LR LS LU LY MA MD ME MG MK MN MW MX MY MZ NA NG NI NO NZ OM PA PE PG PH PL PT QA RO RS RU RW SA SC SD SE SG SK SL ST SV SY TH TJ TM TN TR TT TZ UA UG US UZ VC VN WS ZA ZM ZW
ARIPO: BW GH GM KE LR LS MW MZ NA RW SD SL ST SZ TZ UG ZM ZW
EAPO: AM AZ BY KG KZ RU TJ TM
EPO: AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
OAPI: BF BJ CF CG CI CM GA GN GQ GW KM ML MR NE SN TD TG
ライセンスをご希望の方、特許の内容に興味を持たれた方は、下記までご連絡ください。

PAGE TOP

close
close
close
close
close
close